Clinical Trial News and Research

RSS

FAST-MAG clinical trial finds that magnesium does not improve stroke-related disability

In the first study of its kind, a consortium led by UCLA physicians found that giving stroke patients intravenous magnesium within an hour of symptom onset does not improve stroke outcomes, according to research presented today at the American Stroke Association's International Stroke Conference.

14 Feb 2014

Intravenous magnesium fails to improve stroke-related disability

Giving intravenous magnesium to stroke patients soon after the start of symptoms, in an attempt to protect brain cells deprived of oxygen, failed to improve stroke-related disability 3 months later, according to research presented at the American Stroke Association's International Stroke Conference 2014

13 Feb 2014

FDA accepts Regado Biosciences' IND application for REG2

Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.

13 Feb 2014

FDA grants full approval of SYNRIBO for injection

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA.

13 Feb 2014

GenVec achieves third milestone for development of treatments for hearing and balance disorderstion

GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders.

13 Feb 2014

Cogstate technology to be applied in paediatric clinical trial in the U.S.

Medical technology company Cogstate Limited has today announced its technology will be used in a large paediatric clinical trial in the United States.

12 Feb 2014

PAREXEL launches marketing initiative to simplify journey from science to new treatments

As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.

From Parexel 12 Feb 2014

MIT develops robot that may speed up drug development for stroke patients

The development of drugs to treat acute stroke or aid in stroke recovery is a multibillion-dollar endeavor that only rarely pays off in the form of government-approved pharmaceuticals.

12 Feb 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

11 Feb 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

Omeros announces additional positive data from OMS824 Phase 1 program

Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).

11 Feb 2014

Short-Form OAB questionnaire validated

Researchers from the USA have developed a short form version of the overactive bladder questionnaire, which they say can capture the full spectrum of symptom bother and quality of life impact, while being more convenient than the full version of the test.

10 Feb 2014

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.

10 Feb 2014

KKH doctors develop novel DIVA System for blood pressure management

New trial results1 have shown that the world's first Double Intravenous Vasopressor Automated (DIVA) System affords superior control of maternal blood pressure in women undergoing caesarean section under spinal anaesthesia, when compared with manually-administered medication to manage reduced blood pressure (vasopressor).

10 Feb 2014

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme.

10 Feb 2014

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB).

10 Feb 2014

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.

10 Feb 2014

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.

10 Feb 2014

PHT‘s LogPad App System receives Clinical Informatics News Best Practices Award

The PHT Corporation LogPad App System was a finalist for the Clinical Informatics News Best Practices Awards announced February 6 at the SCOPE Summit for Clinical Ops Executives.

10 Feb 2014

Clinical Trial News and Research

FAST-MAG clinical trial finds that magnesium does not improve stroke-related disability

Intravenous magnesium fails to improve stroke-related disability

FDA accepts Regado Biosciences' IND application for REG2

FDA grants full approval of SYNRIBO for injection

GenVec achieves third milestone for development of treatments for hearing and balance disorderstion

Cogstate technology to be applied in paediatric clinical trial in the U.S.

PAREXEL launches marketing initiative to simplify journey from science to new treatments

MIT develops robot that may speed up drug development for stroke patients

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Omeros announces additional positive data from OMS824 Phase 1 program

Short-Form OAB questionnaire validated

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

KKH doctors develop novel DIVA System for blood pressure management

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Mallinckrodt announces commercial launch of PENNSAID

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

PHT‘s LogPad App System receives Clinical Informatics News Best Practices Award

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery